Stevia Corp, STEV, Profile, Summary
Stevia Corp. | STEV | Profile | Summary
Stevia Corp. (STEV) is a farm management company focused on Stevia agronomics from plant breeding to good agricultural practices to development of stevia derived products.
Stevia Corp. invests heavily in R&D and IP acquisition and manages its own propagation, nursery, and plantations as well as provides services to contract growers and other industry growers.
The Company was founded to deliver top quality agribusiness solutions in order to maximize the efficient mass production of stevia leaf and stevia derived products. The Company is headquartered in the US with farm operations/R&D in Vietnam, China, and Indonesia and planned operations in the US.
Read the comprehensive analysis: find out the 'Target Price', market dynamics, the opportunity and meet the excellent management team click here , download the full report!
INVESTMENT HIGHLIGHTS
◊ Opportunity to invest in an early development stage, vertically-integrated stevia farm management company in an emerging, high growth market
◊ The Company plans to be a “one stop shop” agribusiness solutions provider offering the full spectrum of farm management services
o Operate its own plantations, manage contract farms, and service industry growers (read Executive Summary)
o Expects to achieve positive EBITDA by the second quarter of 2013, growing to $3mm in annualized EBITDA by the end of 2013
(read full Investment Highlights)
o Positioned to become a global leader in the stevia industry that maximizes the efficient mass production of stevia leaf and stevia derived products
o Fastest growing product in the alternative sweetener market with 6,000 products across 35 countries
o Expected to eventually replace 20% of the sugar segment of global sweeteners or a $10 billion market opportunity
◊ Our valuation analysis results in a target price of $1.20 per share which represents significant upside of over 4 times the current stock price (see Valuation)
◊ The Company recently secured $500,000 in an equity private placement
and has access to $20 million from Southridge Partners.
◊ Global sweetener market is a $60 billion dollar industry! See the company's growth plans, the advantages of Vertically Integrated Supply Chain and much more...full free report
MANAGEMENT TEAM
Strong Global Executive Team with highly recognized leadership skills, expertise and decades of experience in Three Continents, Four vibrant economic regions of the world (The United States, Europe, Latin America and Asia-Pacific).
George S. Blankenbaker (President)
Mr. Blankenbaker has been leading the development of high Reb-A Stevia farming in Vietnam, where he imported the Morita variety to trial in 2008 and in 2009 signed a contract to supply stevia leaf to PureCircle, the industry's leading refiner. Mr. Blankenbaker first became involved in commercial agriculture in 2002 when he began working with the Agri-Food Veterinary Authority of Singapore (AVA) to provide strategically important food supplies to Singapore. Prior to that Mr. Blankenbaker co-wrote and co-presented a bid for the U.S. Navy Subsistence Prime Vendor (SPV) Contract valued at USD $197 million covering three zones of Japan, Singapore, and Diego Garcia. The contract was awarded in 2002 and the Singapore and Diego Garcia portion is currently supported by the Rong-Yao group, a partner company based in Singapore.
During the 1990s Mr. Blankenbaker was the Managing Director of a foodservice equipment company servicing South East Asia and was a partner of a holding company that established the first broadline foodservice distribution facility in Singapore which was also the first food distribution facility in Singapore to achieve both ISO 9000 and HACCP certification. Mr. Blankenbaker also traded commodities and was an independent consultant and analyst for Standard Chartered Bank and Reuters and was on the implementation team that established Globex in Singapore linking the Singapore International Monetary Exchange with the Chicago Board of Trade. Read more...
Rodney L. Cook (Director)
Dr. Pablo Erat (Director)
Thomas Ong (Director of Operations, Asia)
Dr. Zhang Ji (Chief Technical Advisor)
Dr. Nguyen Van Dan
(Technical Advisor – Vietnam R&D and Propagation Center)
Vincent Tan Meng Sheong (Director of Operations, China)
click here for Management Bios
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Yukon-Nevada Gold,YNG,YNGFF, Profile, Summary
Yukon-Nevada Gold| YNG |YNGFF | Profile | Summary
Yukon-Nevada Gold Corp is listed on the Toronto Stock Exchange (YNG.TO)
and trades on the OTC/Pinksheets under the symbol YNGFF.
Jerritt Canyon, the Company's flagship project, is located in northern Nevada. The Company is currently focused on modernizing the milling facility and emission control systems. The Company is striving to reach a point of renewed profitability accompanied by a significantly reduced environmental impact. Ongoing permitting at Starvation Canyon, Nevada will allow the Company, in the future, to realize an increase in the production of gold ounces at Jerritt Canyon.
The Company is focused on bringing its wholly owned Ketza River property back into production from the Manto Gold Zones and permitting is underway. The Ketza River Property includes the Ketza River mine, which, from 1987 to 1990, produced 98,000 oz of gold and by-product silver from 340,000 tons of ore.
1. Jerritt Canyon - historical production of approximately 8 million oz gold since 1981
+ 100% owned.
+ Permitted and Producing.
+ Current Reserve & Resource includes: 374,800 oz Proven, 686,000 oz Probable, 1.03M oz Measured & 1.29M oz Indicated.
+ Mill engineered capacity of 6,000 tpd of which 5,280 tpd is currently permitted.
2. Ketza River - historical production of 98,000 oz of gold and by-product silver between 1988 - 1990
+ 100% owned.
+ Current Resource includes: 29,000 oz Measured and 388,700 oz Indicated.
+ Site infrastructure well developed.
+ Permitting in progress for mine/mill re-start.
Deutsche Bank invested $40M in equity and $140M gold forward sale.
Planned mine includes 9 open pits and
2 underground declines
+ 83% of the oz to be mined will come from the open pits.
+ Estimated mining rate of 50,000 tpd for the first 2 years and 20,000 tpd in the 3rd year from the open pits.
+ An additional 500 tpd will come from underground mining.
A total of 41% of the measured and indicated recoverable resource ounces are hosted in oxide ores which have a gold recovery of 90%; whereas the other 59% of the measured and indicated recoverable, resource ounces are hosted in sulfide or mixed sulfide+oxide ores that generally have Au recoveries of 70%.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
HOKU, Hoku Corporation, Profile, Summary
Hoku Corporation | HOKU | Profile | Summary
Hoku Corporation (HOKU) is a solar products and services company operating two businesses: Hoku Materials and Hoku Solar. Hoku Materials manufactures, markets and sells polysilicon for the solar industry from its plant currently under construction in Pocatello, Idaho. Hoku Solar is a leading provider of commercial solar power, offering turnkey PV systems and project development services.
Hoku Solar
Hoku Solar – HOKU - is a leading provider of investment-grade solar power, offering project development services, turnkey PV system integration and asset management for solar energy facilities.
Hoku Solar focuses primarily on the commercial and industrial solar market segment, providing large-scale rooftop or ground-mounted PV arrays for businesses, institutions and government clients. We have proven experience with specialty and technical solar products, including third party financed purchase power agreements (PPAs), and building integrated PV. Hoku is also increasingly engaged in the multi-megawatt utility scale market, both as a project developer and as an EPC service provider.
Hoku Solar is active in Hawaii, and is expanding its project development business to other U.S. markets.
Hoku Solar Services
Turnkey PV Integration
Hoku Solar is a full-service solar industry EPC contractor, providing its customers with turnkey engineering, procurement, and construction services for investment-grade PV.
Hoku Solar primarily serves commercial and industrial rooftop customers, large real estate portfolio holders and developers, general contractors, and government and institutional clients.
With proven experience in the Hawaii market, Hoku can deliver a full range of commercial systems, ranging from individual rooftop arrays to multi-megawatt ground-mounted systems.
Project Development
With our unique design and development service offering, Hoku Solar is positioned to bring large-scale and portfolio PV projects to life, whether as lead developer, or as a complement to an existing project team.
Hoku Solar has proven experience at every stage of the PV development cycle – from feasibility studies to commissioning and take-out financing – and we tailor our services to the individual needs of the project. So, whether Hoku is leading the development itself, or contributing to a broader effort, we are focused on scaling up solar in the U.S.
Contact us today and let us put our experience to work for you.
Asset Management
Underperforming solar arrays are underperforming investments. Hoku Solar has the engineering, technical and operational experience to help ensure your target returns are achieved.
We offer customized operations and maintenance programs for a wide variety of commercial systems, each designed to enhance overall system performance and reliability. From system assessment to preventative and corrective maintenance and monitoring, let Hoku Solar’s asset management team help guarantee your PV system’s long-term performance.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have any questions, please don't hesitate to contact
the Editor [@ ] OxBridgeResearch.com
Hemispherx Biopharma, HEB, Profile, Summary
Hemispherx Biopharma | HEB | Profile | Summary
Hemispherx Biopharma (HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®.
Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in New Brunswick, New Jersey.
ALFERON
Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.
Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.
ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.
Clinically Effective:
-
All warts disappeared in 54% of patients.3
-
No recurrence in 76% of complete responders at follow-up.3
-
Completely cleared 73% of all treated warts.3,4
-
No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
-
Provides a spectrum of multiple alpha interferon subtypes.1,
What's in the Pipeline?
Ampligen® (poly I:poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching. Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza.
Watch This!
On July 31, 2012 Hemispherx submitted its complete response to the FDA’s Complete Response Letter in support of Ampligen®’s New Drug Application for Chronic Fatigue Syndrome (“CFS”).
Its too early to tell what the FDA's response would be, however, the response from investors has been very positive. We alerted our members and followers last week and we believe this company should be on your radar!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Feed Entries
